Cargando…
Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide
OBJECTIVE: The objective of this retrospective study was to evaluate whether the effect of second-line therapy of flutamide after bicalutamide can predict the response to abiraterone. RESULTS: Thirty-four patients received abiraterone and 32 received enzalutamide after treatment with second-line flu...
Autores principales: | Nakai, Yasushi, Tanaka, Nobumichi, Miyake, Makito, Inoue, Takeshi, Anai, Satoshi, Fujimoto, Kiyohide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975444/ https://www.ncbi.nlm.nih.gov/pubmed/29843816 http://dx.doi.org/10.1186/s13104-018-3453-z |
Ejemplares similares
-
Amrubicin is effective against small cell carcinoma of the prostate as a second‐line chemotherapeutic agent: A case report
por: Maesaka, Fumisato, et al.
Publicado: (2019) -
Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) – comparison between 2004–2006, 2007–2009, and 2010–2012
por: Tanaka, Nobumichi, et al.
Publicado: (2017) -
Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade
por: Yokomizo, Yumiko, et al.
Publicado: (2016) -
Review by urological pathologists improves the accuracy of Gleason grading by general pathologists
por: Nakai, Yasushi, et al.
Publicado: (2015) -
Impact of Radical Nephrectomy and Partial Nephrectomy on Actual Estimated Overall Survival Compared to Life Expectancy in Patients with Renal Cell Carcinoma
por: Hori, Shunta, et al.
Publicado: (2021)